15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Intra-Cellular Therapies Inc. (ITCI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pentwater Capital Management Matthew Halbower | 5,190,000 | $684,664,800 | 5.75% | |
| 2. | Davidson Kempner Thomas Lenox Kempner | 3,485,058 | $459,748,851 | 9.46% | |
| 3. | Farallon Capital Thomas Steyer | 3,055,000 | $403,015,600 | 2.25% | |
| 4. | Balyasny Asset Management Dmitry Balyasny | 2,257,912 | $297,863,751 | +1517% | 0.49% |
| 5. | Citadel Investment Group Ken Griffin | 2,237,131 | $295,122,321 | +1796% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $29.60 | 49,500 | $1,465,200.00 | 4,743,770 | 2020-09-14 | Filing | |
| $28.08 | 21,000 | $589,680.00 | 4,694,270 | 2020-09-11 | Filing | |
| $11.00 | 6,240 | $68,640.00 | 4,673,270 | 2019-09-10 | Filing | |
| $10.58 | 320,095 | $3,386,605.10 | 4,667,030 | 2019-09-10 | Filing | |
| $9.59 | 155,116 | $1,487,562.44 | 4,346,935 | 2019-09-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $84.69 | 1,534 | $129,914.00 | 1,070,329 | 2024-12-05 | Filing | |
| $84.06 | 50,163 | $4,216,927.51 | 1,071,863 | 2024-12-05 | Filing | |
| $86.00 | 23,333 | $2,006,750.00 | 1,070,329 | 2024-12-04 | Filing | |
| $85.62 | 27,667 | $2,368,909.41 | 1,093,662 | 2024-12-04 | Filing | |
| $88.92 | 5,343 | $475,099.56 | 0 | 2024-11-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,519,968 | $1,255,874,178 | 0.02% | |
| 2. | 8,754,966 | $1,154,955,049 | 0.02% | |
| 3. | 3,091,133 | $407,782,265 | 33.23% | |
| 4. | 2,662,273 | $351,206,975 | 0.02% | |
| 5. | 1,831,951 | $241,741,213 | 0.02% |
News See All
12 Best Psychedelic Stocks to Buy in 2025
In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality." One class of hallucinogenic substances that can produce unusual states of...
Why These 15 Stocks Are Skyrocketing in 2025
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation.
Why These 10 Large-Cap Stocks are Skyrocketing
On January 23, Mike Bailey, FBB Capital Partners director of research, appeared on CNBC where he shared his outlook on the large caps.
Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer commented on the devastation ushered in by the California wildfire calamity, social media CEO Mark Zuckerberg's appearance on the Joe ...
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Call Transcript
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q3 2024 Earnings Call Transcript October 30, 2024Intra-Cellular Therapies, Inc. misses on earnings expectations.
10 Most Promising Mid-Cap Stocks According to Hedge Funds
September closed on a high note, opening a wealth of opportunities for investors.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q2 2024 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to Intra-Cellular Therapies Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Hedge Funds Like Intra-Cellular Therapies (NASDAQ:ITCI)
The healthcare industry is considered to be a fairly defensive sector due to its need.